Lung Cancer Trial, Recruiting NCT06907160 Sponsor: Yonsei University Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06907160
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with stage II or stage III lung cancer, confirmed through a tissue sample (biopsy)
  • People whose lung cancer does not have specific genetic changes known as EGFR mutations or ALK alterations
  • People who are generally well enough to carry out daily activities with little to no limitation (rated 0 or 1 on a standard activity scale used by doctors)
  • People who are 19 years of age or older
  • People who have signed a form giving their informed consent to take part in the trial

Who may not be able to join:

  • People who are under 19 years of age
  • People who have a history of serious infections or other significant medical conditions that affect their ability to function or follow the trial's requirements
  • People whom the trial investigator judges to be unable to follow the trial's procedures and requirements, including those who lack the capacity to make medical decisions
  • People whom the trial director determines to be unsuitable for other reasons, including pregnant women

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: (82)10-3487-6255

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
7 August 2024
Est. completion
28 February 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Pathologic response after surgery, assessed according to IASLC pathologic response criteria, including major pathologic response and pathologic complete response in resected specimens following neoadjuvant CIT.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov